33376-96-4

Usage

Uses

Used in Pharmaceutical Industry:
5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-AMINE is used as a key intermediate in the synthesis of various pharmaceutical drugs due to its unique triazolopyrimidine structure, which can be leveraged to develop new therapeutic agents.
Used in Agrochemicals:
In the agrochemical industry, 5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-AMINE is utilized as a building block for the development of new agrochemicals, potentially offering novel solutions for pest and disease control in agriculture.
Used in Antiviral Applications:
5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-AMINE is used as an antiviral agent for its potential to inhibit viral replication and activity, offering a new avenue for treating viral infections.
Used in Antifungal Applications:
5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-AMINE is also used as an antifungal agent, leveraging its ability to combat fungal infections, which is crucial in both medical and agricultural settings.
Used in Anticancer Applications:
5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-AMINE is used as an anticancer agent, where its biological activity has shown promise in targeting and inhibiting the growth of cancer cells, making it a valuable candidate for cancer drug development.
These applications highlight the versatility and potential impact of 5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-AMINE across different sectors, particularly in healthcare and agriculture, where its unique properties can be harnessed to address significant challenges.

InChI:InChI=1/C6H7N5/c1-4-2-5(7)11-6(10-4)8-3-9-11/h2-3H,7H2,1H3

Upstream product

• 24415-66-5 7-Chloro-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine 
• 35523-67-2 4,7-dihydro-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine 
• 61-82-5 3⁽⁵⁾-amino-1,2,4-triazole 
• 70807-22-6 3-hydroxycrotononitrile sodium salt 
• 2503-56-2 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 

Relevant academic research and scientific papers

Anti-diabetic and anti-parasitic properties of a family of luminescent zinc coordination compounds based on the 7-amino-5-methyl-1,2,4-triazolo[1,5-a]pyrimidine ligand

We report on the formation of a triazolopyrimidine derivative ligand, 7-amino-5-methyl-1,2,4-triazolo[1,5-a]pyrimidine (7-amtp), and a new family of coordination compounds based on this ligand and zinc as metal ion, synthesized by conventional routes. These materials possess different mononuclear structures, namely [ZnCl2(7-amtp)2] (1), [Zn(7-amtp)2(H2O)4](NO3)2·2(7-amtp)·6H2O (2) and [Zn(7-amtp)2(H2O)4](SO4)·1.5H2O (3) derived from the use of different zinc (II) salts, in such a way that the counterions govern the crystallization to a large extent. These compounds present and show variable luminescent properties based on ligand-centred charge transfers which have been deeply studied by Time Dependent Density Functional Theory (TD-DFT) calculations. When these compounds are transferred to solution, preserving complex entities as corroborated by NMR studies, they present interesting anti-diabetic and anti-parasitic capabilities, with a comparatively higher selectivity index than other previously reported triazolopyrimidine-based materials. The results derived from in vivo experiments conducted in mice also confirm their promising activity as anti-diabetic drug being capable of dropping glucose levels after oral administration. Therefore, these new materials may be considered as excellent candidates to be further investigated in the field of luminescent coordination compounds with biomedical applications.

TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS

The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.